Olivier Louis Chinot

11PUBLICATIONS
97CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyAcute careMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 02, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

|Mar 16, 2026
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.

Francesco Sanvito, Catalina Raymond, Donatello Telesca

|Oct 02, 2024
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Salah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret

|Feb 23, 2024
Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial.

Alexandre Carpentier, Roger Stupp, Adam M Sonabend

|Jul 14, 2022
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.

Caroline Houillier, Sylvain Dureau, Luc Taillandier

|Jun 30, 2022
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study.

Paul Lesueur, Gandhi Damaj, Khê Hoang-Xuan

Pageof 2

Frequent Collaborators

3 joint publications

Wolfgang Wick

3 joint publications

Michael Weller

3 joint publications

Martin J van den Bent

3 joint publications

Johan M Kros